Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking. In step 1 ...

PARIS — The long-acting injectable cabotegravir (ViiV Healthcare), previously shown to be safe and effective for the prevention of HIV in men, is also safe and effective in women, new data show.

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has ...

Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on HIV news from the IDWeek annual meeting: Moderator Monica Gandhi, MD, MPH, of the University of California ...

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...

CHICAGO — The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ...

LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that ...

Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. In this phase 3, open-label, multicenter, ...